Hjem › Steatotisk leversygdom › Utah
Steatotisk leversygdom kliniske forsøg i Utah
5 studier for Steatotisk leversygdom søger deltagere på steder i Utah.
Byer i Utah
Officiel studietekst (engelsk)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Care Access - Ogden, Ogden
- Advanced Research Institute - Sandy, Sandy City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07165028A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, West Jordan
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 17. sep. 2026 · NCT07221188A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Ogden
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Sandy City
- 89bio Clinical Study Site, West Jordan
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 3. sep. 2026 · NCT06419374A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, West Jordan
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 27. jul. 2026 · NCT07221227Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.